Cisplatin and 5-fluorouracil in refractory breast cancer patients: a phase II study

Breast Cancer Res Treat. 1988 Jul;11(3):269-71. doi: 10.1007/BF01807286.

Abstract

24 patients with a median of 3 prior chemotherapy regimens were treated in our department with cisplatin 20 mg/m2 (with pre- and posthydration) and 5-fluorouracil 200 mg/m2 i.v. on day 1-5, every three weeks. 23 patients are evaluable; one had early death. 4 patients (17%) achieved a partial response, 8 had stable disease, and 11 progressed. Toxicity observed was moderate and no renal toxicity was noted. This study therefore shows tolerable toxicity but limited usefulness of adding cisplatin to 5-fluorouracil according to this schedule in these highly pretreated patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Cisplatin / administration & dosage*
  • Drug Evaluation
  • Female
  • Fluorouracil / administration & dosage*
  • Humans
  • Middle Aged

Substances

  • Cisplatin
  • Fluorouracil